Product
Belatacept
Aliases
Belatacept Injection, Nulojix
Name
NULOJIX
INN Name
BELATACEPT
FDA Approved
Yes
12 clinical trials
1 organization
11 indications
1 document
Indication
Heart TransplantIndication
Kidney TransplantationIndication
Immune suppressionIndication
Heart Transplant FailureIndication
Kidney TransplantIndication
End Stage Renal Disease (ESRD)Indication
Chronic Kidney FailureIndication
Renal Transplant RecipientIndication
Renal Allograft RecipientsIndication
Kidney DiseasesIndication
Kidney Transplant InfectionClinical trial
Belatacept in De Novo Heart Transplantation - Pilot StudyStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Use of Donor Derived-cell Free DNA (AlloSure) to Facilitate Belatacept Monotherapy in Kidney Transplant PatientsStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss TherapyStatus: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal FailureStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Novel Desensitization Protocol With Proteasome Inhibitor and Costimulation Blockade for Highly Sensitized Patients to Allow for Successful Kidney Transplantation. A Pilot Study.Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft DysfunctionStatus: Recruiting, Estimated PCD: 2027-05-03
Clinical trial
Late Abatacept Conversion in Kidney Transplant Recipients Receiving Belatacept: a Prospective, Randomized Controlled Non-inferiority Trial. IM101-884Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive MedicationsStatus: Recruiting, Estimated PCD: 2026-05-25
Clinical trial
Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients <BELAFENDO>Status: Not yet recruiting, Estimated PCD: 2028-01-01
Clinical trial
Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.Status: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
Advancing Transplantation Outcomes in Children (CTOT-41)Status: Recruiting, Estimated PCD: 2028-11-01
Clinical trial
Belatacept With Delayed Tacrolimus Withdrawal Versus Standard-of-Care Tacrolimus in Heart Transplant Recipients (RTB-013)Status: Not yet recruiting, Estimated PCD: 2028-01-31
Document
DailyMed Label: NULOJIXOrganization
E.R. Squibb & Sons, L.L.C.